Literature DB >> 25559809

Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.

Daniel Chubb1, Peter Broderick1, Matthew Frampton1, Ben Kinnersley1, Amy Sherborne1, Steven Penegar1, Amy Lloyd1, Yussanne P Ma1, Sara E Dobbins1, Richard S Houlston2.   

Abstract

PURPOSE: Knowledge of the contribution of high-penetrance susceptibility to familial colorectal cancer (CRC) is relevant to the counseling, treatment, and surveillance of CRC patients and families. PATIENTS AND METHODS: To quantify the impact of germline mutation to familial CRC, we sequenced the mismatch repair genes (MMR) APC, MUTYH, and SMAD4/BMPR1A in 626 early-onset familial CRC cases ascertained through a population-based United Kingdom national registry. In addition, we evaluated the contribution of mutations in the exonuclease domain (exodom) of POLE and POLD1 genes that have recently been reported to confer CRC risk.
RESULTS: Overall mutations (pathogenic, likely pathogenic) in MMR genes make the highest contribution to familial CRC (10.9%). Mutations in the other established CRC genes account for 3.3% of cases. POLE/POLD1 exodom mutations were identified in three patients with family histories consistent with dominant transmission of CRC. Collectively, mutations in the known genes account for 14.2% of familial CRC (89 of 626 cases; 95% CI = 11.5, 17.2).
CONCLUSION: A genetic diagnosis is feasible in a high proportion of familial CRC. Mainstreaming such analysis in clinical practice should enable the medical management of patients and their families to be optimized. Findings suggest CRC screening of POLE and POLD1 mutation carriers should be comparable to that afforded to those at risk of HNPCC. Although the risk of CRC associated with unexplained familial CRC is in general moderate, in some families the risk is substantive and likely to be the consequence of unidentified genes, as exemplified by POLE and POLD1. Our findings have utility in the design of genetic analyses to identify such novel CRC risk genes.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25559809     DOI: 10.1200/JCO.2014.56.5689

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Knowledge and Awareness of Colorectal Cancer Early Warning Signs and Risk Factors among University Students in Jordan.

Authors:  Nizar M Mhaidat; Belal A Al-Husein; Karem H Alzoubi; Dima I Hatamleh; Youcef Khader; Sinaa Matalqah; Abla Albsoul
Journal:  J Cancer Educ       Date:  2018-04       Impact factor: 2.037

2.  Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.

Authors:  Kara N Maxwell; Steven N Hart; Joseph Vijai; Kasmintan A Schrader; Thomas P Slavin; Tinu Thomas; Bradley Wubbenhorst; Vignesh Ravichandran; Raymond M Moore; Chunling Hu; Lucia Guidugli; Brandon Wenz; Susan M Domchek; Mark E Robson; Csilla Szabo; Susan L Neuhausen; Jeffrey N Weitzel; Kenneth Offit; Fergus J Couch; Katherine L Nathanson
Journal:  Am J Hum Genet       Date:  2016-05-05       Impact factor: 11.025

Review 3.  Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.

Authors:  Stephanie R Barbari; Polina V Shcherbakova
Journal:  DNA Repair (Amst)       Date:  2017-06-09

Review 4.  Translational Research in Familial Colorectal Cancer Syndromes.

Authors:  Molly M Ford
Journal:  Clin Colon Rectal Surg       Date:  2018-05-01

Review 5.  Current Approaches to Pediatric Polyposis Syndromes.

Authors:  Aodhnait S Fahy; Christopher R Moir
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

6.  Expanding the spectrum of germline variants in cancer.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Sandeep Kumar Parvathareddy; Ismail A Al-Badawi; Nasser Al-Sanea; Luai H Ashari; Alaa Abduljabbar; Samar Alhomoud; Saif S Al-Sobhi; Asma Tulbah; Dahish Ajarim; Khalid Alzoman; Muna Aljuboury; Hussam Bin Yousef; Mohammed Al-Dawish; Fouad Al-Dayel; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Hum Genet       Date:  2017-10-03       Impact factor: 4.132

7.  ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.

Authors:  Qingfu Xu; Chengchen Hu; Yan Zhu; Kimberly Wang; Bachuchu Lal; Lichao Li; Junhai Tang; Shuang Wei; Guohao Huang; Shuli Xia; Shengqing Lv; John Laterra; Yugang Jiang; Yunqing Li
Journal:  Cancer Lett       Date:  2020-01-16       Impact factor: 8.679

Review 8.  Advances in Hereditary Colorectal and Pancreatic Cancers.

Authors:  Meghan L Underhill; Katharine A Germansky; Matthew B Yurgelun
Journal:  Clin Ther       Date:  2016-04-02       Impact factor: 3.393

Review 9.  A panoply of errors: polymerase proofreading domain mutations in cancer.

Authors:  Emily Rayner; Inge C van Gool; Claire Palles; Stephen E Kearsey; Tjalling Bosse; Ian Tomlinson; David N Church
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

10.  Population Landscape of Familial Cancer.

Authors:  C Frank; M Fallah; J Sundquist; A Hemminki; K Hemminki
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.